Brought to you by 
CKD gets rights to sell S1's Lorexys in South Korea
10 Dec 2015
Executive Summary
S1 Biopharma Inc. granted Chong Kun Dang Pharmaceutical Corp. (CKD) rights to commercialize its sexual dysfunction therapy Lorexys (bupropion/trazodone) in South Korea, once approved.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CKD gets rights to sell S1's Lorexys in South Korea
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice